Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1709
    +0.0015 (+0.13%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • Bitcoin GBP

    55,738.11
    +95.38 (+0.17%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Drugmaker Hikma expects 2017 revenue at the lower end of guidance

Aug 17 (Reuters) - Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) said on Thursday it expected 2017 revenue at the lower end of its guidance, after increased competition in the generics business hit prices and volumes.

The Jordan-based company, which makes and markets branded and non-branded generic and injectable drugs, said it now expected 2017 revenue to be about $2 billion, at the lower end of its previous forecast of $2 billion-$2.1 billion.

In May, London-listed Hikma cut full-year guidance for the first time to the range of $2 billion-$2.1 billion at constant currency, down from $2.2 billion.

Hikma also lowered full-year revenue guidance for the second time in its generics business to about $620 million in 2017, from its previous forecast of $670 million. Hikma's initial forecast was $800 million.

ADVERTISEMENT

The drugmaker also said in May that U.S. regulators decided not to approve its generic version of GlaxoSmithKline Plc (Other OTC: GLAXF - news) 's blockbuster lung drug Advair, citing "major" issues with the application.

The company reported a 1 percent rise in revenue to $895 million for the six months ended June 30, while core operating profit of $176 million was in line with last year.

(Reporting By Justin George Varghese in Bengaluru; Editing by Edmund Blair)